AUS
NZ
UK
CA
USA
IND
Adheris Health Limited (ASX:AHE) has submitted a Final Director's Interest Notice confirming that Sean Slattery ended his tenure as a director on 1 July 2026. This filing, made under ASX Listing Rule 3.19A.3 and section 205G of the Corporations Act, reveals that Slattery held no securities in the company at the time of his departure. The notice finalizes Slattery's directorship, prompting the company to update its board composition and governance accordingly.
Key Points
- Company: Adheris Health Limited (ASX:AHE), ABN 17 145 327 617
- Director Sean Slattery ceased his role effective 1 July 2026
- Final Director's Interest Notice filed under ASX Listing Rule 3.19A.3 and Corporations Act section 205G
- Slattery held no registered or beneficial securities in Adheris Health upon departure
- No director interests in contracts were declared in the notice
- Investors should monitor for any announcements on board restructuring or new appointments
Sean Slattery’s Departure from Adheris Health Confirmed as of 1 July 2026
Adheris Health Limited has officially confirmed via a regulatory filing that Sean Slattery resigned as a director on 1 July 2026. The Final Director's Interest Notice, required under ASX Listing Rule 3.19A.3, was lodged to fulfill disclosure requirements at the conclusion of his directorship. The notice references a previous filing dated 29 August 2025 as Slattery’s last interest notice while serving on the board.
A director’s departure typically initiates governance and administrative updates, such as changes to board committees, authorized signatories, and remuneration arrangements linked to board service. Although the filing does not detail the reasons behind Slattery’s exit, it serves as a routine but vital disclosure ensuring transparency in board changes for ASX-listed companies.
Disclosure Obligations Under the Final Director's Interest Notice
According to ASX Listing Rule 3.19A.3, a listed entity must lodge a Final Director's Interest Notice when a director leaves office. This document must detail the director’s securities interests at departure—both direct and beneficial—as well as any contractual interests with the company. The rule ensures the market receives a full and accurate record of the departing director’s financial ties to the company at exit.
Adheris Health complied by submitting the Appendix 3Z form, which also fulfills requirements under section 205G of the Corporations Act 2001. This section mandates directors to notify the company of relevant interests, reinforcing the emphasis Australian regulators place on transparency regarding director securities holdings.
Sean Slattery Held No Securities in Adheris Health at Departure
The Final Director's Interest Notice reveals that Sean Slattery held zero securities in Adheris Health at the time he stepped down. Part 1 of the notice, covering direct registered holdings, records nil, as does Part 2, which covers indirect or beneficial interests through entities like trusts or nominees.
This absence of holdings means Slattery’s departure does not impact the company’s share register or present any immediate risk of on-market selling related to his exit. Shareholders and Market Participants tracking insider holdings will note there is no selldown risk associated with this board change.
No Contractual Interests Declared in the Filing
Part 3 of the Appendix 3Z addresses director interests in contracts with the company. For Slattery’s final notice, this section is recorded as nil, indicating no contractual relationships existed or required disclosure at the time of his departure. This information is relevant to investors assessing potential impacts on commercial agreements or related-party dealings.
The consistent nil disclosures across registered securities, beneficial interests, and contract interests portray a director without financial ties to the company via shareholdings or contracts. The notice does not specify whether Slattery received termination payments, board fees upon cessation, or other entitlements, as these are not required disclosures under Appendix 3Z.
Potential Impact on Adheris Health’s Board Composition
The departure of a board member naturally raises questions about governance and whether a replacement will be appointed. This filing does not indicate any plans to fill Slattery’s vacancy. Investors should watch for future announcements regarding board restructuring, committee membership changes, or new director appointments.
Adheris Health is expected to maintain a board of adequate size and diversity per ASX Corporate Governance Principles and Recommendations. Whether Slattery’s exit creates a skills gap or affects committee structures is not addressed here and would require further company communications or periodic reports for clarification.
Interval Between Slattery’s Last Interest Notice and Departure
The Final Director's Interest Notice notes Slattery’s previous interest notice was lodged on 29 August 2025, with his cessation on 1 July 2026—approximately ten months later. Any securities changes during that period would have been subject to separate notifications under ASX Listing Rule 3.19A.2, requiring disclosure within five business days.
The nil holdings at departure suggest no material changes occurred during this interval. Investors seeking a full history of Slattery’s disclosures should review all filings available on Adheris Health’s ASX profile, as the Final Director's Interest Notice only reflects the endpoint of his tenure.
Adheris Health’s Compliance with Corporations Act Section 205G
Beyond ASX Listing Rules, this filing also meets obligations under section 205G of the Corporations Act 2001, which requires directors to notify the company of relevant securities interests, including upon leaving office. The company then submits this information to the ASX for public access. This dual requirement highlights the importance Australian law places on director-level transparency in listed companies.
By lodging the Appendix 3Z on Slattery’s behalf, Adheris Health acts as the intermediary between the departing director and the market. This information is now publicly accessible to investors, analysts, and market participants interested in the company’s governance history. No further details regarding board plans or strategic direction post-departure were disclosed.
Investor Implications of the Director’s Departure
For Adheris Health investors, the Final Director's Interest Notice serves mainly as a governance and compliance update rather than an operational or financial signal. Nonetheless, board composition is a critical factor in evaluating a company’s strategic oversight and governance quality. Changes at the director level, especially involving board size or expertise, can be significant for investors conducting due diligence on management and leadership.
The immediate effect on the company’s share price from this filing was not evident. Investors should monitor any future updates addressing board reconstitution, director appointments, or governance strategy. This notice should be considered alongside Adheris Health’s broader financial disclosures, including its latest Annual Report, half-year results, and guidance.
Upcoming Developments to Monitor in Adheris Health Governance
The next key development for investors will be whether Adheris Health announces a new director appointment or issues updates on board composition following Slattery’s exit. Under ASX Listing Rule 3.19A.1, any new director must lodge an initial director’s interest notice within five business days of appointment, providing insight into incoming board members’ holdings.
Investors may also look to the company’s next quarterly activity report, Annual General Meeting notice, or corporate governance statement for additional context on board management. Material governance changes, including committee formations or reconstitutions, are typically disclosed formally. Until then, this Final Director's Interest Notice marks the official conclusion of Sean Slattery’s directorship at Adheris Health Limited.
